Flourish Research, a multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas, has acquired Diablo Clinical Research, a multi-therapeutic clinical research facility performing phase I-IV clinical trials and medical device studies.

Established in 1995 and headquartered in Walnut Creek, CA, Diablo has conducted more than 1,000 trials across various therapeutic areas, establishing a strong track record in endocrinology, cardiovascular, and metabolic studies, among others.

Reinhold Schulz, Chief Executive Officer of Flourish, said, “For 30 years, Diablo has built its reputation as a premier regional site, delivering high participant diversity, top enrollment-to-target statistics and participant retention. Diablo expands our geographic footprint and adds additional therapeutic area coverage. As a result, we can provide patients with best-in-class service and deliver to our clients accurate and timely data to support new and improved therapies.”

Emily Galdes, Chief Operating Officer of Diablo, added, “The missions of Flourish and Diablo are identical – advancing clinical research to bring life-enhancing therapies to market safely and effectively. By joining Flourish, our experienced principal investigators, management team, and staff can combine expertise that will be of great value to our sponsors and participants.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.